Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile

Abstract

Our results show that high-risk subjects with triple-positive aPL profiles are identified early, at the time of the initial screening tests.

Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles

“…Our data show that even under other conditions, the presence of anti IgG anti Dm4/5 is not associated with thromboembolic events. These antibodies are mainly found in individuals with isolated IgG aβ2GP1 positivity that is often not confirmed after 12 weeks [18]. It may be that the transient nature of single IgG aβ2GP1 positivity is due to the presence of these antibodies, however this needs confirmation in 'ad hoc' studies.…”

Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant

“…A limitation of this study is the long term follow up of patients as not all the enrolling centers tested for LA every year in a systematic way. In clinical practice, when LAC is the only positive test, three considerations should be made: (i) the risk of thrombosis is low; (ii) LAC may be false positive in particular when it is weak or borderline [12]; (iii) sole LAC positivity is often not confirmed after 12 weeks [30]. In conclusion, results from this study support the data coming from some body of literature that the sole LAC positivity does not expose the carriers to high risk of thrombosis.…”

Receptors involved in cell activation by antiphospholipid antibodies

“…Studies on the predictive pathogenic value of the different types of aPLA seem to indicate that antibodies with biological lupus anticoagulant activity (LA) as well as antibodies against β2GP1 or anticardiolipin (aCL) correlate with a history of thrombo-embolic complications and pregnancy morbidity. Patients that are triple positive for LA, anti-β2GP1 and aCL antibodies have the highest risk of complication [3,4].…”